Achievements

We are conducting Open Collaboration actively to improve our research capacities

Microneedles are a type of transdermal drug delivery system in the form of patches, utilizing ultra-fine needles—approximately one-third the thickness of human hair—to penetrate the stratum corneum and deliver drugs through the skin. This innovative technology offers a more patient-friendly alternative to injectable formulations.
Through joint research with Daewoong Therapeutics, Daewoong Pharmaceutical has established its proprietary microneedle platform technology and is striving to become the global leader in microneedle-based therapeutics.

Proprietary Platform Technology (Dissolving Microneedles): Through its CLOPAM technology, Daewoong ensures product stability by fully embedding each microneedle into the mold, preventing exposure to the external environment. The drug is localized at the tip of each microneedle to maximize delivery efficiency.

Mass Production Technology: Daewoong has secured automated manufacturing capabilities and established facilities to produce clinical trial materials. A new cGMP-compliant manufacturing plant is under construction to support future commercial-scale production.

Open Collaboration: Daewoong’s Yongin R&D Center houses a dedicated GMP facility for microneedle production, approved through regulatory inspection. This enables end-to-end collaborative development—from formulation research to clinical trial materials and drug manufacturing.

Next-Generation Platform Development: Daewoong is advancing next-generation microneedle technologies that address the limitations of existing systems. These advancements include increased drug-loading capacity, tunable release profiles, and detachable microneedle structures to further enhance delivery efficiency and user convenience.